

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Cyrus Rustam Kumana and Yok-Lam Kwong

Serial No.: 10/669,869 Art Unit: 1616

Filed: September 23, 2003 Examiner: Frank I. Choi

For: **FORMULATION OF ORAL COMPOSITIONS COMPRISING ARSENIC TRIOXIDE AND METHODS OF USE**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF REFERENCES CITED IN SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Further to the Supplemental Information Disclosure Statement (IDS) filed in the above-identified application on October 31, 2007, enclosed are copies of the six (6) documents (listed below) which were in bold and marked with an asterisk in the Supplemental IDS, and which Applicants indicated would be submitted under separate cover subsequent to the filing of the Supplemental IDS.

Publications

*BERENSON, et al., "A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma", *Clin Lymphoma*, 5(2):130-4 (2004).

*JANNE, "Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations", *Semin Oncol.*, 32(6 Suppl 10):S9-15 (2005).

U.S.S.N.: 10/669,869
Filed: September 23, 2003
SUBMISSION OF REFERENCES CITED IN
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

*NI, et al., "Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia", *Chin Med J (Engl)*, 111(12):1107-10 (1998).

*POMERANTZ and GRANDIS, "The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy", *Semin Oncol*, 31(6):734-43 (2004).

*YAMAUCHI, et al., "Metabolism and excretion of orally administrated arsenic trioxide in the hamster", *Toxicology*, 34(2):113-21 (1985).

*YANG and FRENKEL, "Arsenic-mediated cellular signal transduction, transcription factor activation, and aberrant gene expression: implications in carcinogenesis", *Environ Pathol Toxicol Oncol*, 21(4):331-42 (2002).

Consideration of the enclosed references is earnestly requested.

Respectfully submitted,

/Patrea L. Pabst/
Patrea L. Pabst
Reg. No. 31,284

Dated: March 10, 2008

PABST PATENT GROUP LLP
400 Colony Square, Suite 1200
1201 Peachtree Street
Atlanta, Georgia 30361
(404) 879-2151 (Telephone)
(404) 879-2160 (Fax)